MeSH D017086 - beta-thalassemia
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Mylan | Deferasirox | Deferasirox Mylan | 2019-09-26 | |||
| Novartis | Deferasirox | Exjade | 2006-08-28 | $647 M | Q2/19-Q2/22 | |
| Bristol Myers Squibb | Luspatercept | Reblozyl | 2020-06-25 | $1,897 M | Q2/24-Q1/25 | |
| Accord Healthcare | Deferasirox | Deferasirox Accord | 2020-01-09 | |||
| Chiesi Farmaceutici | Deferiprone | Ferriprox | 1999-08-25 | |||
| Lipomed | Deferiprone | Deferiprone Lipomed | 2018-09-19 | |||
| bluebird bio | Betibeglogene autotemcel | Zynteglo | 2022-08-17 | $62.273 M | Y2024 |
Clinical Trials
Historical Success Rate
Phase 1
55%12/22
Phase 2
54%22/41
Phase 3
60%12/20
Approved: 5Overall Success rate: 18%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use